Cogent Biosciences, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2016 | — | $-24.7M | $42.6M |
| Mar 2017 | — | — | $34.5M |
| Jun 2017 | — | — | $32.5M |
| Sep 2017 | — | — | $32.0M |
| Dec 2017 | — | $-48.8M | $28.3M |
| Mar 2018 | — | $-61.3M | $25.7M |
| Jun 2018 | — | $76.7M | $46.7M |
| Sep 2018 | — | $67.5M | $49.3M |
| Dec 2018 | — | $60.2M | $55.7M |
| Mar 2019 | — | $49.3M | $59.1M |
| Jun 2019 | — | $39.8M | $55.9M |
| Sep 2019 | — | $28.6M | $45.9M |
| Dec 2019 | — | $31.8M | $37.4M |
| Mar 2020 | — | $25.7M | $29.6M |
| Jun 2020 | — | $19.2M | $21.3M |
| Sep 2020 | — | $-22.2M | $129.4M |
| Dec 2020 | — | $234.7M | $242.2M |
| Mar 2021 | — | $226.8M | $230.7M |
| Jun 2021 | — | $212.8M | $218.1M |
| Sep 2021 | — | $197.2M | $202.9M |
| Dec 2021 | — | $214.2M | $219.7M |
| Mar 2022 | — | $187.9M | $191.0M |
| Jun 2022 | — | $319.4M | $325.6M |
| Sep 2022 | — | $289.9M | $140.6M |
| Dec 2022 | — | $255.7M | $139.9M |
| Mar 2023 | — | $223.6M | $160.7M |
| Jun 2023 | — | $348.4M | $214.3M |
| Sep 2023 | — | $302.9M | $86.8M |
| Dec 2023 | — | $257.8M | $53.2M |
| Mar 2024 | — | $422.3M | $215.8M |
| Jun 2024 | — | $373.2M | $88.2M |
| Sep 2024 | — | $314.7M | $97.0M |
| Dec 2024 | $0 | $256.3M | $98.2M |
| Mar 2025 | — | $219.0M | $126.0M |
| Jun 2025 | $43.9M | $155.0M | $127.6M |
| Sep 2025 | $44.3M | $302.5M | $125.3M |
| Dec 2025 | $222.9M | $636.4M | $312.0M |
| Mar 2026 | $223.2M | $607.7M | $241.2M |
| Jun 2026 | $223.5M | $532.4M | $181.2M |